Acacia Pharma raises £15 million to advance clinical development of lead products for supportive care

09-Sep-2013 - United Kingdom

Acacia Pharma announced it has raised £15 million (~$23.5 million) in a Series B financing led by Fidelity Biosciences and Novo A/S. Current investors Gilde Healthcare and Lundbeckfond Ventures also participated in the round. Dr Alex Pasteur of Fidelity Biosciences and Dr Martin Edwards of Novo A/S have joined the Board of Acacia Pharma as Non-executive Directors.

Acacia Pharma will use the proceeds to:

  • complete Phase III development of APD421 for the prevention of post-operative nausea & vomiting (PONV);
  • complete Phase II development of APD403 for the prevention of chemotherapy induced nausea & vomiting (CINV); and
  • develop the commercial presentation of APD515 for the treatment of xerostomia (dry mouth) in advanced cancer patients.

Other news from the department research and development

More news from our other portals

All FT-IR spectrometer manufacturers at a glance